Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase1 study to evaluate the long toxicology and pharmacological dosing of T20K

Trial Profile

A phase1 study to evaluate the long toxicology and pharmacological dosing of T20K

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T-20K (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Cyxone
  • Most Recent Events

    • 02 Aug 2019 According to a Cyxone media release, Based on the results from the first dose level achieving the study objective, a higher dose level will not need to be studied.
    • 02 Aug 2019 Results presented in the Cyxone media release.
    • 12 Jul 2019 According to a Cyxone media release, company will make a further announcement once the final healthy male volunteer in the second cohort has received his last dose.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top